402 related articles for article (PubMed ID: 10404594)
1. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
3. The pp60c-Src inhibitor PP1 is non-competitive against ATP.
Karni R; Mizrachi S; Reiss-Sklan E; Gazit A; Livnah O; Levitzki A
FEBS Lett; 2003 Feb; 537(1-3):47-52. PubMed ID: 12606029
[TBL] [Abstract][Full Text] [Related]
4. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation.
Yamaguchi H; Hendrickson WA
Nature; 1996 Dec; 384(6608):484-9. PubMed ID: 8945479
[TBL] [Abstract][Full Text] [Related]
9. Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding.
Tong L; Warren TC; Lukas S; Schembri-King J; Betageri R; Proudfoot JR; Jakes S
J Biol Chem; 1998 Aug; 273(32):20238-42. PubMed ID: 9685372
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for selective inhibition of Src family kinases by PP1.
Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
[TBL] [Abstract][Full Text] [Related]
11. Structure of the regulatory domains of the Src-family tyrosine kinase Lck.
Eck MJ; Atwell SK; Shoelson SE; Harrison SC
Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222
[TBL] [Abstract][Full Text] [Related]
12. Structural investigation of the binding of a herpesviral protein to the SH3 domain of tyrosine kinase Lck.
Schweimer K; Hoffmann S; Bauer F; Friedrich U; Kardinal C; Feller SM; Biesinger B; Sticht H
Biochemistry; 2002 Apr; 41(16):5120-30. PubMed ID: 11955060
[TBL] [Abstract][Full Text] [Related]
13. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
14. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
15. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
[TBL] [Abstract][Full Text] [Related]
18. Discovery of thienopyridines as Src-family selective Lck inhibitors.
Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
[TBL] [Abstract][Full Text] [Related]
19. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
Jacobs MD; Caron PR; Hare BJ
Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071
[TBL] [Abstract][Full Text] [Related]
20. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.
Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH
J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
